HIGHLIGHTS
- who: Danai Dima and colleagues from the Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA have published the research work: Multiple Myeloma Therapy: Emerging Trends and Challenges, in the Journal: Cancers 2022, 4082 of 23/08/2022
- what: This trial assessed the addition of Azacytidine, a DNA methylation inhibitor, to lenalidomide and dexamethasone with the purpose of overcoming refractoriness to IMiD via interfering with pathways associated with PC differentiation, apoptosis, and immune recognition.
- how: Another . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.